This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Leukemia	Tet methylcytosine dioxygenase 1 (TET1)	<p>Studies in patient samples and in mice suggest inhibiting TET1 could help treat mixed lineage leukemia (MLL). In MLL patient samples, TET1 expression was greater than that in samples from normal controls. In a mouse xenograft model for MLL, small hairpin RNA against <i>Tet1</i> delayed leukemia growth and increased survival compared with control shRNA. Next steps include screening for small molecule inhibitors of TET1.</p> <p><i>SciBX</i> 6(30); doi:10.1038/scibx.2013.788 Published online Aug. 8, 2013</p>	Patent and licensing status undisclosed	<p>Huang, H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 1, 2013; doi:10.1073/pnas.1310656110 Contact: Jianjun Chen, The University of Chicago, Chicago, Ill. e-mail: jchen@medicine.bsd.uchicago.edu Contact: Janet D. Rowley, same affiliation as above e-mail: jrowley@bsd.uchicago.edu</p>